Appeal for access to cystic fibrosis 'superdrug'
A new drug has shown great promise in treating cystic fibrosis, but its high cost has raised fears that it may not be widely available, writes Susan Mitchell.
It is difficult, if not impossible, to reflect the level of excitement that a blue capsule called Kalydeco elicited when it was first approved for use in the United States. Forbes dubbed it "the most important new drug of 2012" while the Food and Drug Administration (FDA) in the United States described it as a "breakthrough therapy".
Kalydeco is the first - and only - approved drug to treat the underlying cause of cystic fibrosis (CF)...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine